Key terms
About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALKS news
Mar 27
5:55am ET
Alkermes management to meet with Piper Sandler
Mar 25
7:12am ET
Alkermes management to meet with Piper Sandler
Mar 18
4:29pm ET
Alkermes initiated with an Outperform at Baird
Mar 07
7:23am ET
Alkermes Expands Board, Elects Nancy Lurker as New Director
Feb 26
7:10am ET
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
Feb 20
7:01am ET
Alkermes downgraded to Sell from Neutral at UBS
Feb 18
11:46pm ET
Hold Rating on Alkermes Amid Competitive Uncertainty and Limited Growth Prospects
Feb 16
9:13am ET
Alkermes price target raised to $33 from $30 at BofA
Feb 16
8:35am ET
Alkermes price target raised to $39 from $35 at Piper Sandler
Feb 16
7:38am ET
Piper Sandler Remains a Buy on Alkermes (ALKS)
Feb 16
6:07am ET
Alkermes price target raised to $35 from $34 at H.C. Wainwright
Feb 16
5:09am ET
Alkermes: Hold Rating Affirmed Amid EBITDA Growth and Strategic Acquisitions, Balanced by Cautious Sales Outlook
Feb 15
9:35pm ET
Alkermes: A Strong Buy on Path to Profitability, Strategic Capital Allocation, and Pipeline Momentum
Feb 15
7:07am ET
Alkermes sees 2024 revenue $1.5B-$1.6B, consensus $1.52B
Feb 15
7:06am ET
Alkermes reports Q4 non-GAAP EPS 22c, consensus 51c
Feb 13
5:21am ET
Buy Rating Assigned to Alkermes’s Stock Following Promising TAK-861 Trial Outcomes
Feb 12
8:26am ET
Piper Sandler Keeps Their Buy Rating on Alkermes (ALKS)
Feb 09
6:06am ET
Maintaining Hold on Alkermes Amid Narcolepsy Drug Development Uncertainties and Competitive Dynamics
Feb 06
4:54am ET
Alkermes Announces Interim Financial Leadership Appointments
Jan 29
6:55pm ET
Alkermes Buy Rating Affirmed: Profitability and Expansion in Neuroscience Poised for Growth
Jan 26
12:48am ET
Buy Rating Affirmed on Alkermes’s Stock Amid Strong Earnings and Positive 2024 Outlook
Jan 11
1:57am ET
Alkermes Poised for Growth: Strong Sales and Promising Pipeline Justify Buy Rating
Jan 09
8:27am ET
Alkermes: Strong Buy Rating Amidst Robust 2024 Outlook and Promising OX2 Franchise Prospects
Jan 03
7:51am ET
Analysts Offer Insights on Healthcare Companies: Green Thumb Industries (OtherGTBIF), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)
Jan 03
7:03am ET
Alkermes reports results from Phase 3 study of LYBALVI
Jan 02
8:55am ET
Alkermes price target raised to $29 from $27 at BofA
No recent news articles are available for ALKS
No recent press releases are available for ALKS
ALKS Financials
Key terms
Ad Feedback
ALKS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALKS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range